Immunohistochemical evaluation of vimentin aberrant expression in lung carcinoid tumors
https://doi.org/10.17650/2313-805X-2018-5-4-104-109
Abstract
Objective: to the study of the vimentin aberrant expression in the carcinoid tumors of lung, which is a rare group of epithelial neuroendocrine neoplasms with common morphological characteristics and highly variable clinical course.
Materials and methods. Vimentin expression was studied using immunohistochemical analysis in neoplasms of 34 patients with lung carcinoid tumors, which included 17 cases in the categories of typical and atypical carcinoids.
Results. Overall positive cytoplasmic immunoreactivity was observed in 9 (26.5 %) of the 34 studied tumors. Staining for vimentin was positive in 2 (11.8 %) of typical carcinoid and in 7 (41.2 %) of atypical carcinoid specimens. Expression of vimentin was more often observed in the atypical carcinoids category and was significantly associated with increased grade (p = 0.05), and cell proliferation taking into account the Ki-67 index (p = 0.008).
Conclusion. These results suggest that expression of vimentin as an epithelial-mesenchymal transition-related marker plays an important role in the progression of carcinoid tumors. It may prove useful for diagnostic purposes, and also be used as a potential criterion for prognosis assessment of this type of tumors.
About the Authors
V. V. Delektorskaya
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
G. Yu. Chemeris
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
E. A. Smirnova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
References
1. Travis W.D., Brambilla E., Burke A.P. et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. IARC Press: Lyon, 2015.
2. Rindi G., Klersy C., Inzani F. et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer 2013;21(1):1–16. DOI: 10.1530/ERC-13-0246. PMID: 24344249.
3. Delektorskaya VV Neuroendocrine tumors of the lung: the current classification and pathology diagnosis algorithm. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2017;4(2):46—58. (In Russ.)
4. Davis F.M., Stewart T.A., Thompson E.W., Monteith G.R. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci 2014;35(9):479—88. DOI: 10.1016/j.tips.2014.06.006. PMID: 25042456.
5. Mittal V. Epithelial mesenchymal transition in aggressive lung cancers. Adv Exp Med Biol 2016;890:37-56. DOI: 10.1007/978-3-319-24932-2_3. PMID: 26703798.
6. Zhang Y., Weinberg R.A. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med 2018;12(4):361 —73 DOI: 10.1007/s11684-018-0656-6. PMID: 30043221.
7. Prieto-Garcia E., Diaz-Garcia C.V., Gar-cia-Ruiz I., Agullo-Ortuno M.T. Epitheli-al-to-mesenchymal transition in tumor progression. Med Oncol 2017;34(7):122.
8. Vasilenko I.V., Kondratyuk R.B., Kudryashov A.G. et al. The features of epithelial-mesenchymal transition in cancers of various localizations and histological structure. Klinicheskaya onkologiya = Clinical Oncology 2012;5(1):163—7. (In Russ.).
9. Qureshi R., Arora H., Rizvi M.A. EMT in cervical cancer: its role in tumour progression and response to therapy. Cancer Lett 2015; 356(2 Pt B):321—31. DOI: 10.1016/j.canlet.2014.09.021. PMID: 25281477.
10. Kidd M.E., Shumaker D.K., Ridge K.M. The role of vimentin intermediate filaments in the progression of lung cancer. Am J Respir Cell Mol Biol 2014;50(1):1— 6. DOI: 10.1165/rcmb.2013-0314TR. PMID: 23980547.
11. Du L., Li J., Lei L. et al. High vimentin expression predicts a poor prognosis and progression in colorectal cancer: a study with meta-analysis and TCGA database. Biomed Res Int 2018;2018:6387810. DOI: 10.1155/2018/6387810. PMID: 29955607.
12. Singla M., Kumar A., Bal A. et al. Epithelial to mesenchymal transition induces stem cell like phenotype in renal cell carcinoma cells. Cancer Cell Int 2018;18:57. DOI: 10.1186/s12935-018-0555-6. PMID: 29681769.
13. Satelli A., Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 2011;68(18):3033—46. DOI: 10.1007/s00018-011-0735-1. PMID: 21637948.
14. Fendrich V., Maschuw K., Waldmann J. et al. Epithelial-mesenchymal transition is a critical step in tumorgenesis of pancreatic neuroendocrine tumors. Cancers (Basel) 2012;4(1):281—94. DOI: 10.3390/can-cers4010281. PMID: 24213240.
15. Yonemori K., Kurahara H., Maemura K. et al. Impact of Snail and E-cadherin expression in pancreatic neuroendocrine tumors. Oncol Lett 2017;14(2):1697—702. DOI: 10.3892/ol.2017.6306. PMID: 28789397.
16. Galvan J.A., Astudillo A., Vallina A. et al. Prognostic and diagnostic value of epithelial to mesenchymal transition markers in pulmonary neuroendocrine tumors. BMC Cancer 2014;14:855. DOI: 10.1186/1471-2407-14-855. PMID: 25413006.
17. Ponomarenko E.A., Bogush T.A., Mamichev I.A. et al. Expression of vimentin — molecular marker of cell metastatic potential in tissues of nonsmall cell lung cancer and stomach cancer. Zlokachestvennye opukholi = Malignant Tumors 2017;7(3):89. (In Russ.).
Review
For citations:
Delektorskaya V.V., Chemeris G.Yu., Smirnova E.A. Immunohistochemical evaluation of vimentin aberrant expression in lung carcinoid tumors. Advances in Molecular Oncology. 2018;5(4):104-109. (In Russ.) https://doi.org/10.17650/2313-805X-2018-5-4-104-109
Views:
645
Email this article 